Uveitis is a combined condition of inflammation and swelling of the eyes. Uvea comprises of three parts Iris, ciliary body (small ring shape muscles behind iris and choroid), and choroid (it is the layer of tissue between retina and sclera), which decides eye color and helps eye in focusing and absorbing light. Uveitis can be caused by eye problems, autoimmune disease, HIV, multiple sclerosis, reactive arthritis, Kawasaki disease tuberculosis, and syphilis. Uveitis can affect people between the ages of 16 to 60 years, sometimes it may lead to permanent loss of vision. According to the National Center for Biotechnology Information (NCBI), uveitis counts for 10% to 15% of overall blindness. Treatments available for of uveitis include steroids, immunosuppressant, and monoclonal antibodies. Surgeries are performed in rare cases. Various pharmaceutical companies are working on R&D to launch new and effective medication for the treatment of uveitis, which is expected to boost the uveitis market.
Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/842
Uveitis treatment market taxonomy
By Indication
- Anterior uveitis
- Intermediate uveitis
- Posterior uveitis
- Pan uveitis
By Cause
- Infectious
- Non infectious
By Condition
- Acute
- Chronic
- Recurrent
By Drug
- Corticosteroids
- Immunosuppressant
- Monoclonal antibodies
- Cycloplegic agents
- Antibodies
- Antiviral
- Antifungals
- Analgesics
Research and development fuels the growth of uveitis treatment market
Several companies such as Pfizer Inc., pSivida Corp., and Novartis AG are investing in R&D to produce novel drug for the treatment of uveitis. There are few drugs already in pipeline such as Sirolimus, dexamethasone phosphate, rituximab, which will boost the uveitis treatment market. Increase in demand of generic drugs is also expected to support the growth of uveitis treatment market. Uveitis are caused by infections such as cat-scratch disease, herpes zoster, and ulcerative colitis. According to NCBI report, 17.4 to 52.4 cases per 100000 person every year takes place and it causes 2.8 -10% of legal blindness in the U.S annually. Corticosteroids are the most commonly used treatment for uveitis as compared to other drugs such as biologics, immunosuppressant. After corticosteroids antibiotics and monoclonal antibodies are mostly used for the treatment. Side effects of medication such as blurred vision, weight gain, insomnia, and increased appetite could be the major restraint for the growth of the uveitis market. Lack of awareness in emerging economies can lead to chronic eye disease and vision loss.
Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/uveitis-treatment-market-842
Developed regions are major growth engines of the uveitis treatment market
Market comprises of regions that is North America, Latin America, Europe, Asia Pacific, the Middle East and Africa. North America is the largest region and emerging market for uveitis treatment globally. Europe is the second largest emerging market which support the growth of global uveitis treatment market. After Europe, Asia pacific is the third largest growing market which includes emerging countries like India and China, owing to the increase in healthcare facilities and awareness people among the people, which will support the growth of uveitis treatment market.
Key players and major acquisitions to support the growth of uveitis treatment market
Key players operating global uveitis market include Allergan, Novartis AG, Valeant Pharmaceuticals International, AbbVie Inc., Eyegate Pharmaceuticals Inc., and pSivida corp. Allergan, Novartis and Valeant Pharmaceuticals International, Inc. are most dominant players in the market. Major acquisition takes place in this market include
- In 2016, Allergan acquired a gene therapy company name Retrosome Therapeutics, which strengthen their ophthalmology drug pipeline. In the same year Allergan launched uveitis drug Taytulla.
- In 2016, Novartis acquired Encore vision, which help to enhance their ophthalmology drug pipeline
- In 2015, Eyegate signed a licensing agreement with valeant for effective combination of drugs for uveitis and in 2016 they acquired Jade Therapeutics Inc.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
No comments:
Post a Comment